Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn't a myth

Nicole DeFeudis

Editor

While most biotech startups begin with a light bulb moment or in-licensed technology, Mythic Therapeutics’ roots trace back to a dining room table and an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn't a myth

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Rid­ing an ADC hot streak, a new biotech bets a megaround that a bet­ter ver­sion of those ther­a­pies is­n't a myth

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn't a myth